biostudies-literatureEarly Breast Cancer Trialists' Collaborative Group (EBCTCG)NCATS NIH HHSCancer Research UKMedical Research CouncilNational Institute for Health Research (NIHR)NCI NIH HHS1440-1452https://www.ebi.ac.uk/biostudies/studies/S-EPMC6451189biostudies-literatureUnknown393(10179)<h4>Background</h4>Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy.<h4>Methods</h4>To clarify the relative benefits and risks of dose-intense and standard-schedule chemotherapy in early breast cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The primary outcomes were recurrence and breast cancer mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, and trial, yielded dose-intense versus standaLancet (London, England)Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.PMC6451189MC_U137686850UL1 TR00037127691NF-SI-0512-10122P30 CA0087482113325351MC_U137686858NF-SI-0616-10107MC_UU_12026/1Mackey JCufer TMavroudis DGelmon KWood WHarbeck NKilburn LFountzilas GDolci SYarnold JJagsi RPierce LCirrincione CColeman RJames SJackisch CBrain EZambetti MTaylor CUntch MRutgers EMartin MBurrett JCuzick JBruzzi PIngle JNorton LFisher BBartelink HPoortmans PGiuliano MCostantino JForbes JJulien JPDavies LLevine MBamia CTutt ADavies CEwertz MViale GPastorino SMacKinnon EBartlett JGeyer CLarsimont DBass GCorrea CPiedbois PGettins LShao YFShepherd LCoates AGerber BDodwell DMuss HRaina VBlohmer JUGray RDi Leo APaik SMannu GChia SPeer PA'Hern RMobus VCosta SBradley RNogaret JMPiccart MOhashi YSadoon MCarrasco ESteger GRegan MBarlow WGodwin JDe Laurentiis MArriagada RFoukakis TBergsten Nordstrom EMukai HClarke MTulusan AHPater JBergh JShan YDel Mastro LHill CMamounas EPLoibl SBogaerts JWang XWang YParulekar WGoodwin PWang ZBraybrooke JEvans VDignam JRea DBroadwater GTu DEllis PCarey LBerry Dvan de Velde CChen BRedmond CPritchard KISegui MAvon Minckwitz GDuane FVliek SDe Placido SGnant MRakovitch EBighin CSertoli MRRavdin PDavidson NLinn SGelber RKoliou GAWolmark NLiu HPhilippson CMorden JRead SBoddington CAnderson SCameron DAlbain KPeto RSwain SHayes DZhao DBWickerham DLGoldhirsch ALiu ZMorris PBramwell VHEarly Breast Cancer Trialists' Collaborative Group (EBCTCG)Francis PXu BWeiss RBoccardo FSparano JTjan-Heijnen VGoss PVenturini MPronzato PMcGale PBliss JPan HFasching PBijker NDowsett MSlamon DNekljudova VHills RWilcken NMcHugh TCardoso FRobertson JJanni WWhelan TfalseIncreasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.<h4>Background</h4>Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy.<h4>Methods</h4>To clarify the relative benefits and risks of dose-intense and standard-schedule chemotherapy in early breast cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The primary outcomes were recurrence and breast cancer mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, and trial, yielded dose-intense versus standa2019-01-01T00:00:00Z2019 Apr2026-05-06T21:34:17.837Z2019-06-06T21:07:08ZS-EPMC64511893073974310.1016/S0140-6736(18)33137-4